Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 6, 2006, Pages 1937-1945

  Kiser, Tyree H ^a   Hoody, Dorie W ^b   Obritsch, Marilee D ^c   Wegzyn, Colleen O ^b   Bauling, Paulus C ^a   Fish, Douglas N ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BURN; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG HALF LIFE; FEMALE; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; THERMAL INJURY;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BURNS; COMPUTER SIMULATION; FEMALE; HALF-LIFE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; OFLOXACIN; TREATMENT OUTCOME;

EID: 33744486890     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01466-05     Document Type: Article

References (36)

1. Bjerknes, R., H. Vindenes, and O. D. Laerum. 1990. Altered neutrophil functions in patients with large burns. Blood Cells 16:127-141.
2. Bonate, P. L. 1990. Pathophysiology and pharmacokinetics following burn injury. Clin. Pharmacokinet. 18:118-130.
3. Boucher, B. A., S. R. King, H. L. Wandschneider, W. L. Hickerson, S. D. Hanes, V. L. Herring, T. W. Canada, and M. M. Hess. 1998. Fluconazole pharmacokinetics in burn patients. Antimicrob. Agents Chemother. 42:930-933.
4. Bourget, P., A. Lesne-Hulin, R. Le Reveille, H. Le Bever, and H. Carsin. 1996. Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob. Agents Chemother. 40:139-145.
5. Chow, A. T., A. Chen, H. Lattime, N. Morgan, F. Wong, C. Fowler, and R. R. Williams. 2002. Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses. J. Clin. Pharm. Ther. 27:143-150.
6. Chow, A. T., C. Fowler, R. R. Williams, N. Morgan, S. Kaminski, and J. Natarajan. 2001. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 45:2122-2125.
7. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
8. Craig, W. A. 1998. Pharmacokinctic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
9. Demling, R. H. 1985. Burns. N. Engl. J. Med. 313:1389-1398.
10. Drusano, G. L., S. L. Preston, C. Fowler, M. Corrado, B. Weisinger, and J. Kahn. 2004. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis. 189:1590-1597.
11. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
12. Garrelts, J. C., G. Jost, S. F. Kowalsky, G. J. Krol, and J. T. Lettieri. 1996. Ciprofloxacin pharmacokinetics in burn patients. Antimicrob. Agents Chemother. 40:1153-1156.
13. Garrelts, J. C., and J. D. Peterie. 1988. Altered vancomycin dose vs. serum concentration relationship in burn patients. Clin. Pharmacol. Ther. 44:9-13.
14. Graham, D. R., D. A. Talan, R. L. Nichols, C. Lucasti, M. Corrado, N. Morgan, and C. L. Fowler. 2002. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin. Infect. Dis. 35:381-389.
15. Hasslen, S. R., R. D. Nelson, T. K. Kishimoto, W. E. Warren, D. H. Ahrenholz, and L. D. Solem. 1991. Down-regulation of homing receptors: a mechanism for impaired recruitment of human phagocytes in sepsis. J. Trauma 31:645-651.
16. Lacy, M. K., W. Lu, X. Xu, P. R. Tessier, D. P. Nicolau, R. Quintiliani, and C. H. Nightingale. 1999. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumonias in an in vitro model of infection. Antimicrob. Agents Chemother. 43:672-677.
17. Lister, P. D. 2003. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J. Antimicrob. Chemother. 51:199-202.
18. Lister, P. D., and C. C. Sanders. 1999. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 43:79-86.
19. Madaras-Kelly, K. J., B. E. Ostergaard, L. B. Hovde, and J. C. Rotschafer. 1996. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 40:627-632.
20. Mattoes, H. M., M. Banevicius, D. Li, C. Turley, D. Xuan, C. H. Nightingale, and D. P. Nicolau. 2001. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:2092-2097.
21. Mileski, W., D. Borgstrom, E. Lightfoot, R. Rothlein, R. Faanes, P. Lipsky, and C. Baxter. 1992. Inhibition of leukocyte-endothelial adherence following thermal injury. J. Surg. Res. 52:334-339.
22. Neuhauser, M. M., R. A. Weinstein, R. Rydman, L. H. Danziger, G. Karam, and J. P. Quinn. 2003. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289:885-888.
23. Nguyen, T. T., D. A. Gilpin, N. A. Meyer, and D. N. Herndon. 1996. Current treatment of severely burned patients. Ann. Surg. 223:14-25.
24. Ortho-McNeil Pharmaceutical. 2005. Levaquin (levofloxacin) prescribing information. Ortho-McNeil Pharmaceutical, Raritan, N.J.
25. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129.
26. Rebuck, J. A., D. N. Fish, and E. Abraham. 2002. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 22:1216-1225.
27. Shah, V. P., K. K. Midha, J. W. Findlay, H. M. Hill, J. D. Hulse, I. J. McGilveray, G. McKay, K. J. Miller, R. N. Patnaik, M. L. Powell, A. Tonelli, C. T. Viswanathan, and A. Yacobi. 2000. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17:1551-1557.
28. Shargel, L., and A. B. C. Yu. 1999. Applied biopharmaceutics and pharmacokinetics, 4th ed. Appleton & Lange, Stamford, Conn.
29. Walstad, R. A., L. Aanderud, and E. Thurmann-Nielsen. 1988. Pharmacokinetics and tissue concentrations of ceftazidime in burn patients. Eur. J. Clin. Pharmacol. 35:543-549.
30. Warden, G. D., A. D. Mason, Jr., and B. A. Pruitt, Jr. 1974. Evaluation of leukocyte chemotaxis in vitro in thermally injured patients. J. Clin. Investig. 54:1001-1004.
31. Weinbren, M. J. 1999. Pharmacokinetics of antibiotics in burn patients. J. Antimicrob. Chemother. 44:319-327.
32. Wong, F. A., S. J. Juzwin, and S. C. Flor. 1997. Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine. J. Pharm. Biomed. Anal. 15:765-771.
33. Wright, D. H., G. H. Brown, M. L. Peterson, and J. C. Rotschafer. 2000. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46:669-683.
34. Zaske, D. E., R. J. Sawchuk, D. N. Gerding, and R. G. Strate. 1976. Increased dosage requirements of gentamicin in burn patients. J. Trauma 16:824-828.
35. Zaske, D. E., R. J. Sawchuk, and R. G. Strate. 1978. The necessity of increased doses of amikacin in burn patients. Surgery 84:603-608.
36. Zelenitsky, S. A., G. K. Harding, S. Sun, K. Ubhi, and R. E. Ariano. 2003. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J. Antimicrob. Chemother. 52:668-674.